1-1 By: Bonnen (Senate Sponsor - Kolkhorst) H.B. No. 4638 1-2 (In the Senate - Received from the House May 7, 2025; 1-3 May 9, 2025, read first time and referred to Committee on Health & 1-4 Human Services; May 26, 2025, reported favorably by the following 1-5 vote: Yeas 8, Nays 0; May 26, 2025, sent to printer.)

1-6

COMMITTEE VOTE

1-7	7	Zea	Nay	Absent	PNV		
1-8		X	nay	11000110	1110		
1-9		X					
1-10	Blanco	X					
1-11		X					
1-12		X					
1-13		X					
1-14				Х			
1-15		Х					
1-16		Х					
1-17	A BIL	L TO BE	ENTITLI	ED			
1-18		AN A	СТ				
1-19	relating to the Texas Pharma						
1-20							
1-21		177.00	3(a), Go	vernment	Code, i	s amen	ided
1-22							
1-23				a board	compose	<u>t</u> to b	lve
1-24							1
1-25	SECTION 2. Chapter 2				, is am	lended	by
1-26 1-27					rd momb		****
1-27							
1-28						-	each
1-30		LET IIIS	expii-	ing rebi	uary r	UI C	acii
1-31		hoard	shall he	filled f	or the 1	inevni	red
1-32						menpi	<u></u> cu
1-33						mendeċ	1 to
1-34		_,,,,,,,,	,		,		~ • • •
1-35		ESS PL	AN. Not	later th	an June	1 of e	each
1-36							
1-37							
1-38							
1-39							the
1-40	initiative's organizational						
1-41	(2) establishir						the
1-42				luding o			the
1-43						dividu	ιa⊥s
1-44	described by Section 2177.00						
1-45				ntracting	g ior s	statew	nde
1-46				+		Liona	± 0
1-47 1-48	(B) establ						
1-40 1-49	operate or contract for the central service center, a						
1-49 1 <b>-</b> 50							
1-51			IIDucc	preserrp		ruys	anu
1-52	(C) provid		adva	nced	pharma	aceuti	cal
1-53					priaria	locuci	JOUL
1-54				generic d	lrugs an	d gene	ric
1-55	biological products;			501101 20 0		50110	
1-56		provid	ling gen	e therapi	es and r	orecis	sion
1-57		± · - ·		- <b>Т</b> . —	- 1	. –	_
1-58	•	provi	iding ad	lvanced 1	Laborato	ries	for
1-59							
1-60	of innovative therapeutics a				-		
1-61	(3) establishir				nt comp	liance	e by

1

H.B. No. 4638 board members and personnel with applicable 2-1 laws governing 2-2 conflicts of interest; 2-3 (4) establishing the conditions for state agencies 2-4 that facilitate health plans to participate in the initiative; 2**-**5 2**-**6 (5) identifying potential cost savings from implementation of the initiative; 2-7 (6) identifying the funding and resources needed to 2-8 implement this chapter; 2-9 (7) providing recommendations on best practices and cost savings related to the provision of pharmacy benefits using program utilization; and (8) [(7)] providing other board recommendations, with 2**-**10 2**-**11 2-12 supporting documentation, on continuation of the initiative. 2-13 SECTION 4. Section 2177.010, Government Code, is amended to 2-14 2**-**15 2**-**16 read as follows: Sec. 2177.010. EXPIRATION OF CHAPTER. This chapter expires 2-17 September 1, <u>2031</u> [<del>2025</del>]. SECTION 5. (a) As soon as practicable after the effective date of this Act, the governor shall appoint the governing board members for the Texas Pharmaceutical Initiative as required by Section 2177.003, Government Code, as amended by this Act. 2-18 2-19 2-20 2-21 2-22 (b) Notwithstanding Section 2177.0035, Government Code, as added by this Act, in making the appointments of the governing board members for the Texas Pharmaceutical Initiative under Subsection 2-23 2-24 2**-**25 2**-**26 (a) of this section, the governor shall designate:(1) two members to serve terms expiring February 1, 2-27 2027; 2-28 (2) two members to serve terms expiring February 1, 2029; and 2-29 2-30 (3) one member to serve a term expiring February 1, 2**-**31 2031. 2-32 SECTION 6. This Act takes effect September 1, 2025.

\* \* \* \* \*

2-33

2